RBC Bioscience Corporation (6848) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of RBC Bioscience Corporation stock TWD 17.97, price TWD 20.60, that is 12.8% below the price, quality 57 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range 10.52 TWD – 35.53 TWD · fair‑value band 14.98 TWD – 30.17 TWD · the 20.60 TWD price screens above the 17.97 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow RBC Bioscience in your weekly email
Every Wednesday you see whether RBC Bioscience is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
RBC Bioscience Corporation manufactures and sells reagents and devices for life science and molecular diagnosis Taiwan.
Show moreShow less
It offers MagCore Plus II Automated Nucleic Acid Extractor, a robotic bench-top workstation for nucleic acid purification; MagCore Super Automated Nucleic Acid Extractor, an automated workstation for nucleic acid extraction; and MagCore® EDA Automatic Extraction and Smart PCR Setup, an instrument for nucleic acid extraction and PCR setup pre-treatment.
The company also provides NGS, genomic DNA, viral nucleic acids, and total RNA kits. RBC Bioscience Corporation was founded in 1995 and is based in New Taipei City, Taiwan.
Stock analysis
RBC Bioscience Corporation (6848) currently trades at 20.60 TWD, while our model-based Fair Value estimate is 17.97 TWD, 13% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 25.31 TWD per share, and 10 of the 24 models we run sit above the 20.60 TWD price.
Bear case: the Economic Profit group reads lowest at 8.76 TWD, and 14 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: 14.98 TWD (bear) to 30.17 TWD (bull), the price of 20.60 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
RBC Bioscience Corporation reported revenue of 205M TWD in FY2024 versus 575M TWD in FY2020, a compound −22.7%/yr. Reported net income was 21.6M TWD in FY2024, compounding −37.6%/yr from FY2020.
Key figures
Market cap 294M TWD (≈ $9.0M) Micro · P/E ratio 14.2 · P/S ratio 1.33 · EPS (TTM) 1.47 TWD · Net margin 9.6% · Return on equity 8.1% · Return on assets (EBIT) 10.0% (5-year average) · Operating margin 9.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (low confidence).
What moves the price
The share trades about 24% below its 52-week high and 46% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −13%, 6848 screens richer than that median.
Fair Value models
Bear14.98 TWDFair Value 17.97 TWDBull30.17 TWD
Price 20.60 TWD · Downside -12.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+19.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.9%
’19
’20
’21
’22
’23
’24
What shareholders gained per year (last 5 years), in TWD (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−27.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−27.2%
Dividend (yield on the price)0.0%
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 17%
2024 sits 234% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +1.0% a year for the price.
Compare RBC Bioscience Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 13/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside−12.8% · Above median
Profitability
Return on equity (12 months)8.1% · Top 25%
Return on assets2.8% · Above median
Net margin (12 months)9.6% · Above median
Operating margin (12 months)9.4% · Above median
Growth and dividend
Revenue growth (quarter YoY)0.8% · Above median
Dividend yield (12 months)23.0% · Top 25%
Balance sheet
Debt / equity1.60× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is RBC Bioscience Corporation (6848) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 17.97 TWD versus a price of 20.60 TWD, about 13% lower (overvalued).
What is the fair value of 6848?
Our model-based fair value for RBC Bioscience Corporation is 17.97 TWD (as of Nov 4, 2026), built from audited fundamentals. The current price: 20.60 TWD.
What is the quality score of 6848?
RBC Bioscience Corporation has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for RBC Bioscience Corporation (6848)?
Our model-based price target is the fair value of 17.97 TWD (as of Nov 4, 2026) from 24 valuation models. Cautious scenario 14.98 TWD, optimistic scenario 30.17 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the RBC Bioscience Corporation stock forecast for 2026?
Our models put fair value at 17.97 TWD, about 13% lower versus a price of 20.60 TWD (overvalued). Cautious scenario 14.98 TWD, optimistic scenario 30.17 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of RBC Bioscience Corporation (6848)?
RBC Bioscience Corporation reported trailing-twelve-month revenue of about 221M TWD (latest available figure, as of Nov 4, 2026).
What growth is priced into RBC Bioscience Corporation (6848)?
For today's price to be fair in a discounted-cash-flow model, RBC Bioscience Corporation would have to grow free cash flow by +2.6 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.9 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of 6848 use?
Our models discount RBC Bioscience Corporation at 9.0 %: a base by market capitalisation (nano), damped by beta 0.47, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For RBC Bioscience Corporation that is +2.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has RBC Bioscience Corporation (6848) delivered so far?
Over the past 5 years revenue at RBC Bioscience Corporation grew +4.9 % a year. The price currently implies free-cash-flow growth of +2.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of RBC Bioscience Corporation (6848) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into RBC Bioscience Corporation (+2.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of RBC Bioscience Corporation (6848)?
The free-cash-flow yield on the price is 15.51 %: that much free cash flow RBC Bioscience Corporation produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of RBC Bioscience Corporation (6848)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For RBC Bioscience Corporation it is 17.97 TWD per share (as of Nov 4, 2026), against a price of 20.60 TWD. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is RBC Bioscience Corporation stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 6848 trades above its calculated fair value: price 20.60 TWD, fair value 17.97 TWD, a gap of about −13% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6848?
No. The price is what the market pays today (20.60 TWD); the fair value is what the company's own numbers justify (17.97 TWD). For RBC Bioscience Corporation the two are 2.63 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is RBC Bioscience Corporation worth?
The market values RBC Bioscience Corporation at about 294M TWD (market capitalisation, as of Nov 4, 2026). Per share that is 20.60 TWD; our models calculate a fair value of 17.97 TWD per share.
What do the bullish and bearish scenarios say about 6848?
Our models span a range for RBC Bioscience Corporation: cautious scenario 14.98 TWD, base 17.97 TWD, optimistic 30.17 TWD per share (as of Nov 4, 2026, price 20.60 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6848?
RBC Bioscience Corporation trades at a price-to-earnings ratio of 14.2 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 17.97 TWD is built from several models across several years. Other multiples: P/B 1.2, P/S 1.3, EV/EBITDA 15.0.
How solid is the balance sheet of RBC Bioscience Corporation (6848)?
Balance-sheet figures for RBC Bioscience Corporation (as of Nov 4, 2026): return on equity 8.1%, debt of 1.60 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 6848 from its 52-week high?
RBC Bioscience Corporation trades at 20.60 TWD, about 24% below its 52-week high of 27.00 TWD and 46% above the low of 14.12 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 17.97 TWD is for.
Which stocks are comparable to RBC Bioscience Corporation?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is RBC Bioscience Corporation stock attractive at the current price?
The data as of Nov 4, 2026: price 20.60 TWD, calculated fair value 17.97 TWD (−13%), Quality Score 57/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6848 calculated?
We run RBC Bioscience Corporation through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 17.97 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. RBC Bioscience Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of RBC Bioscience Corporation (6848)?
The closing price on Nov 6, 2026 was 20.60 TWD. Our model-based fair value is 17.97 TWD, about 13% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with RBC Bioscience Corporation right now?
Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (14.98 TWD to 30.17 TWD) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of RBC Bioscience Corporation
How large is the market capitalisation of RBC Bioscience Corporation (6848)?
The market capitalisation of RBC Bioscience Corporation is 294M TWD (≈ $9.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of RBC Bioscience Corporation (6848)?
The price-to-sales ratio of RBC Bioscience Corporation is 1.33 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of RBC Bioscience Corporation (6848)?
Earnings per share at RBC Bioscience Corporation are 1.47 TWD (price ÷ EPS = P/E 14.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of RBC Bioscience Corporation (6848)?
The net margin of RBC Bioscience Corporation is 9.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of RBC Bioscience Corporation (6848)?
The return on equity (ROE) of RBC Bioscience Corporation is 8.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of RBC Bioscience Corporation (6848)?
On an EBIT basis the return on assets of RBC Bioscience Corporation is 10.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of RBC Bioscience Corporation (6848)?
The operating margin of RBC Bioscience Corporation is 9.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at RBC Bioscience Corporation (6848)?
Revenue at RBC Bioscience Corporation is growing +0.8% versus a year earlier (3y avg −6.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at RBC Bioscience Corporation (6848)?
Earnings per share at RBC Bioscience Corporation are growing −22.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does RBC Bioscience Corporation (6848) carry?
The net debt of RBC Bioscience Corporation is 399M TWD (fiscal year 2024, ≈ 8.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch RBC Bioscience Corporation in the live analysis
One click puts RBC Bioscience Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026